139 related articles for article (PubMed ID: 12614193)
21. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
[TBL] [Abstract][Full Text] [Related]
22. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Lynch JJ; Stump GL; Wallace AA; Painter CA; Thomas JM; Kusma SE; Gould RJ; Grossman W
J Am Coll Cardiol; 1999 Sep; 34(3):876-84. PubMed ID: 10483973
[TBL] [Abstract][Full Text] [Related]
23. Comparison of losartan and captopril in ELITE II.
Lye M
Lancet; 2000 Sep; 356(9232):852; author reply 852-3. PubMed ID: 11022949
[No Abstract] [Full Text] [Related]
24. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Dickstein K
Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
[No Abstract] [Full Text] [Related]
25. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
26. The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.
Lapointe N; Pourdjabbar A; Rouleau JL
Can J Cardiol; 2003 Aug; 19(9):994-6. PubMed ID: 12915925
[No Abstract] [Full Text] [Related]
27. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.
Parlakpinar H; Ozer MK; Acet A
Cytokine; 2011 Dec; 56(3):688-94. PubMed ID: 21975128
[TBL] [Abstract][Full Text] [Related]
28. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B; Poole-Wilson P; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
J Card Fail; 1999 Jun; 5(2):146-54. PubMed ID: 10404354
[TBL] [Abstract][Full Text] [Related]
29. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
[TBL] [Abstract][Full Text] [Related]
30. The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Hamon M; Filippi-Codaccioni E;
Lancet; 2002 Dec; 360(9348):1886-7. PubMed ID: 12480397
[No Abstract] [Full Text] [Related]
31. The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Chowdhary S; Townend JN;
Lancet; 2002 Dec; 360(9348):1886. PubMed ID: 12480396
[No Abstract] [Full Text] [Related]
32. The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Martínez-Sellés M;
Lancet; 2002 Dec; 360(9348):1885; author reply 1885. PubMed ID: 12480394
[No Abstract] [Full Text] [Related]
33. The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Fournier A; Andrejak M; Slama M; Godefroy O; Achard JM;
Lancet; 2002 Dec; 360(9348):1885-6. PubMed ID: 12480393
[No Abstract] [Full Text] [Related]
34. [New options against undertreatment].
Pfeffer M
MMW Fortschr Med; 2003 Dec; 145(49):18. PubMed ID: 14963987
[No Abstract] [Full Text] [Related]
35. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
Milicić D
Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
[TBL] [Abstract][Full Text] [Related]
36. Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade.
Youn TJ; Kim HS; Oh BH
Basic Res Cardiol; 1999 Aug; 94(4):246-53. PubMed ID: 10505424
[TBL] [Abstract][Full Text] [Related]
37. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B; Poole-Wilson PA; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
Lancet; 2000 May; 355(9215):1582-7. PubMed ID: 10821361
[TBL] [Abstract][Full Text] [Related]
38. [Acute myocardial infarction].
Sato H
Nihon Rinsho; 2002 Oct; 60(10):2034-8. PubMed ID: 12397703
[TBL] [Abstract][Full Text] [Related]
39. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
Coletta C; Ricci R; Ceci V; Seccareccia F; Rulli F; Mazzuca V; Putini RL; Salustri A; Bottero G; Pasquale M
G Ital Cardiol; 1999 Feb; 29(2):115-24; discussion 125-9. PubMed ID: 10088066
[TBL] [Abstract][Full Text] [Related]
40. Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction.
Hu K; Bahner U; Gaudron P; Palkovits M; Ring M; Fehle A; Kruse B; Ertl G
Basic Res Cardiol; 2001; 96(3):258-66. PubMed ID: 11403419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
